Product Pipeline

Our Goal is to make a Significant Impact on Metabolic Diseases

We are maximizing the potential of innovative molecules to make an impact on metabolic diseases, particularly in type 2 diabetes and NASH. Our commitment is to develop innovative, safe and effective treatment options for patients.

Why Our Focus is on Metabolic Diseases

Type 2 diabetes is one of the world's major health concerns and its incidence is growing rapidly. It is the most common form of diabetes, affecting about 90% of diabetic patients.

The Challenge with the Current Standard of Care

The current standard of care for the majority of patients is limited by the fact that none of the available therapeutic options is satisfactorily effective in controlling the disease and marketed therapeutics are associated with safety and tolerability side effects as well as weight gain and hypoglycemia.

Click chart to enlarge.


Imeglimin is the first orally-available anti-diabetes drug candidate that simultaneously targets all three key organs of diabetes, which includes the pancreas, liver, and muscles.


The steady growing, ~$4B* Japanese diabetes market offers a unique value creation opportunity.  In Japan, China and 11 other Asian countries, Sumitomo Dainippon Pharma is our strategic partner for Imeglimin. For Japan, Poxel and Sumitomo Dainippon Pharma are jointly conducting the Phase 3 TIMES program for Imeglimin, which is being funded by Sumitomo Dainippon Pharma, and they will commercialize the product for this market. In China, South Korea, Taiwan and nine other Southeast Asian countries including Indonesia, Vietnam, Thailand, Malaysia, the Philippines, Singapore, Myanmar, Cambodia, and Laos, Sumitomo Dainippon Pharma will be solely responsible for the development and commercialization of Imeglimin.

View Additional Information

*Decision Resources, September 2014

U.S. and E.U.

The U.S. and European market provides a ~$32B* market opportunity.  We have a strategic development and license agreement with Roivant Sciences for Imeglimin in the U.S., Europe, and other countries worldwide not covered by Poxel’s agreement with Sumitomo Dainippon Pharma. Phase 3 program-related work for Imeglimin in the U.S. and Europe is underway and a clinical trial in type 2 diabetes patients with chronic kidney disease 3b/4 is ongoing.

View Additional Information


PXL770 directly activates adenosine monophosphate-activated protein kinase (AMPK), an enzyme that controls whole-body energy metabolism. Through its unique mechanism of action that directly activates AMPK, PXL770 acts on a very important biological target.  This target has the potential to treat chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis or NASH.

View Additional Information

PXL065 (DRX-065)

PXL065 (DRX-065) (deuterium-stabilized R-pioglitazone), is a mitochondrial pyruvate carrier (MPC) inhibitor that is currently in Phase 1 development. PXL065 (DRX-065) is the R-stereoisomer (single isomer) of pioglitazone. Pioglitazone, a drug approved for the treatment of type 2 diabetes, has demonstrated efficacy in NASH and is currently the only drug recommended in practice guidelines for biopsy-proven NASH patients1. However, pioglitazone’s use has been limited in NASH due to its side effect profile, which includes weight gain, bone fractures and fluid retention. PXL065 (DRX-065), a novel patent-protected drug candidate, offers a new approach for the treatment of NASH with the potential for similar efficacy and a reduction of side effects associated with the parent drug, pioglitazone.

1. J Hepatol. 2016, 64(6),1388-402; Hepatology 2018, 67, 328-357

PXL007 (EYP001)

Through a licensing agreement with Enyo Pharmaceuticals, EYP001, an FXR agonist, is currently conducting Phase 2 trials for the treatment of Hepatitis B and NASH.

View Additional Information

Additional Metabolic Opportunities

The additional deuterium stabilized programs acquired from DeuteRx have potential applications in metabolic, specialty and rare diseases.


Review our scientific publications, as well as posters and presentations.

View Publications

Sign up for email alerts

Be the first to receive breaking news

Sign up today